Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Research Fix-Corp Int'l (BB:FIXC). -- Ignore unavailable to you. Want to Upgrade?

To: rharris who wrote (1587)	3/24/1998 6:44:00 PM
From: hoffy	Respond to of 1845

FDA approval for CPRO. Looks great for them. Should see this back to the old highs at 8 or maybe higher. This was big news for them. FDA Advisory Panel Reviews CellPro's Filing For Label Expansion of the CEPRATE SC System Business Wire - March 24, 1998 16:59 %CELLPRO CPRO %WASHINGTON %MEDICINE %BIOTECHNOLOGY V%BW P%BW ------------------------------------------------------------------------ SEATTLE--(BUSINESS WIRE)--March 24, 1998--CellPro, Incorporated (Nasdaq:CPRO) announced that the FDA's Biological Response Modifiers Advisory Committee earlier today reviewed CellPro data related to its filing for a label expansion for the CEPRATE(R) SC Stem Cell Concentration System to include peripheral blood and tumor purging, and that the committee voted unanimously that the potential benefits of a 100-fold reduction in the number of tumor cells present in an autograft outweighs the potential risks of CD34 selection. The filing for the expanded label indication was based on data submitted to the FDA in October, 1997 from a Phase III clinical trial involving 131 multiple myeloma patients. The trial met both of its primary endpoints by demonstrating equivalent neutrophil engraftment and a mean reduction of 3.3 logs of contaminating myeloma cells. Over half (54%) of the patients treated using the CEPRATE(R) SC System received a stem cell product with no detectable tumor cells by PCR analysis, compared to 14% of the patients prior to selection and 21% of the comparable patients in the unselected arm. The primary safety endpoint of equivalent neutrophil engraftment by day 14 was also achieved. CellPro President and CEO Richard D. Murdock remarked, "We are very pleased with the outcome of today's meeting and the vote of the committee. Our proposed expansion of the CEPRATE(R) SC System label to include peripheral blood and tumor purging is an opportunity to expand the use of our cell separation technology beyond bone marrow. We expect to continue our dialogue with the FDA to finalize details of labeling, and look forward to continuing the development of cell therapy products and opening new alternatives for the treatment of cancer and other diseases."

To: rharris who wrote (1587)	3/24/1998 6:44:00 PM
From: Warren Buffet Jr.	Read Replies (2) \| Respond to of 1845

### ANYONE FOLLOW NET USA Inc. symbol NTSA ### Just started aggresively marketing ther new computer to computer telecomunications software throughout the Asian region. Saves Asian corperations over 65% on telecomunication costs. Impressive timing on there part with the Asian currency devaluation.Stock has slipped under the radar of the market and as a result so dont expect a lot of volume trades until more news comes out. The CEO just announced they feel the stock price is currently undervalued in lew of there agressive growth projections and will buy back an additional 10% of there stock.Currently the stock price is incredably cheap at $.081 with overwhelming upside potential. Be warned this is still a start-up company and a speculative buy.